NovoCure Q1 Earnings Call Highlights

6 days ago 4

MarketBeat

Thu, April 30, 2026 astatine 8:20 AM CDT 7 min read

NovoCure logo

NovoCure (NASDAQ:NVCR) reported first-quarter 2026 results highlighted by double-digit year-over-year maturation successful some progressive patients and nett revenue, driven successful portion by spot extracurricular the U.S. and an aboriginal commercialized ramp for its recently approved pancreatic crab therapy. Executive Chairman Bill Doyle said the institution had “a beardown commencement to the year,” pointing to advancement connected profitability and aggregate expected catalysts aboriginal successful 2026.

Optune PAX motorboat successful pancreatic crab

The biggest improvement successful the 4th was the FDA support and U.S. motorboat of Optune PAX for patients with locally precocious pancreatic cancer. Doyle said doc feedback has been affirmative since PANOVA-3 information were presented and published astatine ASCO past year, noting “broad recognition” of outcomes including extensions successful wide endurance and clip to symptom progression.

→ Palantir Is Down 30%: Noise? Or a Signal to Accumulate?

NovoCure received FDA support connected Feb. 11. In the 7 weeks betwixt support and 4th end, the institution said it certified 868 healthcare providers, including 27 prescribers successful world centers—an country wherever the institution historically saw slower TTFields adoption. Through March 31, NovoCure reported:

169 prescriptions received
90 diligent starts completed
83 patients connected therapy astatine 4th end, with a “backlog of starts successful the funnel”

On reimbursement, the institution highlighted its archetypal large payer sum argumentation for Optune PAX with Elevance Health, which it said covers much than 30 cardinal lives. Management cautioned that it volition instrumentality a fewer quarters to recognize adoption and reimbursement dynamics, but described aboriginal signals arsenic encouraging.

→ Homebuilder Earnings: D.R. Horton Sticks Out arsenic Pulte & NVR Sales Tank

In the Q&A, executives said request metrics for Optune PAX were “multiples” of what NovoCure saw during its lung crab launch, though they did not supply a circumstantial prescriber number for Q1. CEO Frank Leonard said the archetypal uptake has been broad-based crossed assemblage and world sites, adding that immoderate prescribers wrote aggregate prescriptions wrong the archetypal 5 weeks. Leonard besides pointed to investments specified arsenic the company’s HCP Portal, which helium said has reduced administrative load and helped accelerate prescribing.

PANOVA-4 metastatic pancreatic information and RAS inhibitor enactment

During the quarter, NovoCure besides reported top-line results from the Phase II PANOVA-4 proceedings evaluating TTFields therapy with atezolizumab and gemcitabine successful metastatic pancreatic cancer. Doyle said the survey met its superior endpoint, delivering a illness power complaint of 74% versus 48% successful a humanities control. He added that median duration of therapy was 25.6 weeks, which helium characterized arsenic grounds TTFields is feasible successful the metastatic setting.

Read Entire Article